Precision Drilling(PDS)

Search documents
Precision Drilling Announces Renewal of Normal Course Issuer Bid
GlobeNewswire News Room· 2024-09-13 10:00
CALGARY, Alberta, Sept. 13, 2024 (GLOBE NEWSWIRE) -- This news release contains "forward-looking information and statements" within the meaning of applicable securities laws. For a full disclosure of the forward-looking information and statements and the risks to which they are subject, see the "Cautionary Statement Regarding Forward-Looking Information and Statements" later in this news release. Precision Drilling Corporation (Precision or the Company) announced today that the Toronto Stock Exchange (the T ...
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
GlobeNewswire News Room· 2024-09-09 12:00
PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, will present updated data from the VERSATILE-002 trial evaluating first-line treatment with Versamune® HPV (formerly PDS0101) in combination with KEYTRUDA® (pembrolizumab) in patients with HPV16-positive recurrent/metastat ...
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire News Room· 2024-09-03 12:00
PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York Cit ...
Is Precision Drilling (PDS) Stock Undervalued Right Now?
ZACKS· 2024-08-27 14:42
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being unde ...
Despite Fast-paced Momentum, Precision Drilling (PDS) Is Still a Bargain Stock
ZACKS· 2024-08-27 13:50
Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher." Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ...
PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
GlobeNewswire News Room· 2024-08-07 12:00
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the second quarter of 2024 and provide a business update on Tuesday, August 13, 2024, before the market opens. The press release will be available in the In ...
PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer
GlobeNewswire News Room· 2024-08-01 11:45
Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that it has received the official minutes from its meeting with the U.S. Food and Drug Administratio ...
Precision Drilling(PDS) - 2024 Q2 - Earnings Call Transcript
2024-07-31 22:59
Precision Drilling Corporation (NYSE:PDS) Q2 2024 Earnings Conference Call July 31, 2024 1:00 PM ET Company Participants Lavonne Zdunich – Vice President-Investor Relations Kevin Neveu – President and Chief Executive Officer Carey Ford – Chief Financial Officer Conference Call Participants Kurt Hallead – Benchmark Luke Lemoine – Piper Sandler Aaron MacNeil – TD Cowen Waqar Syed – ATB Capital Markets Jamie Kubik – CIBC John Gibson – BMO Capital Markets Operator Good day, and thank you for standing by. Welcom ...
PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time
GlobeNewswire News Room· 2024-07-31 20:01
PRINCETON, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to provide a clinical program update on Thursday, August 1, 2024, at 8:00 a.m. ET. Conference Call Details Date: August 1, 2024 Time: 8:00 a.m. ET Dial-in: 1-877- ...
Precision Drilling (PDS) Surpasses Q2 Earnings and Revenue Estimates
ZACKS· 2024-07-30 22:46
This quarterly report represents an earnings surprise of 269.35%. A quarter ago, it was expected that this oilfield services company would post earnings of $2 per share when it actually produced earnings of $1.88, delivering a surprise of -6%. Precision Drilling, which belongs to the Zacks Oil and Gas - Drilling industry, posted revenues of $313.71 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 1.53%. This compares to year-ago revenues of $316.89 million. The company has ...